Skip to content
Buy This GLP
← Research
Evidence

Semaglutide After Sleeve Gastrectomy: What One Study Found at One Year

A nonrandomized study found greater one-year weight loss in people who received semaglutide early after sleeve gastrectomy.

Editorial profile: Neil SandersBuy This GLP Editorial Team4 min read
Total body weight lost after sleeve gastrectomy+ semaglutidesurgery alone29.7426.326 months35.1430.7312 monthsDrug given months 1-6 only. Not randomized — 103 patients, one center.

A study followed 103 adults with class II or III obesity after sleeve gastrectomy [1]. The evidence on treating weight regain after bariatric surgery addresses a different stage of recovery. In this study, semaglutide began soon after surgery.

What happened at six and twelve months

Forty-eight patients received semaglutide from postoperative month one through month six. The other 55 did not receive semaglutide. At six months, total weight loss averaged 29.74% and 26.32%, respectively. At twelve months, the averages were 35.14% and 30.73% (p = 0.002) [1].

Total weight loss includes weight lost from before surgery. The gap was visible about six months after the scheduled end of treatment. Differences between the groups may account for some or all of the gap.

What the study can tell patients

The study used one center and did not assign treatment at random. Research on GLP-1 timing around bariatric surgery includes studies with other start times. This study did not test which start time works best. Decisions after surgery belong with the bariatric care team.

Frequently asked

When did patients receive semaglutide?
Treatment was scheduled from one through six months after surgery. The study also measured weight at twelve months.
How much weight did each group lose?
At twelve months, total weight loss averaged 35.14% in the group that received semaglutide and 30.73% in the other group.
Can this study establish the best time to start?
The study compared early use with no semaglutide at one center. It did not compare different start times or assign treatment at random.

Sources

  1. [1] Huang YS, Wen J, Wang S, Song Y, Zhou B, Zhang N, Meng H (2026). Early Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study Obesity Surgery. PMID 42174244

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence